The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Triggering global regulatory submissions this year for the treatment of obesity
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Subscribe To Our Newsletter & Stay Updated
